116 related articles for article (PubMed ID: 26942055)
1. Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia.
Martner A; Rydström A; Riise RE; Aurelius J; Anderson H; Brune M; Foà R; Hellstrand K; Thorén FB
Oncoimmunology; 2016; 5(1):e1041701. PubMed ID: 26942055
[TBL] [Abstract][Full Text] [Related]
2. Effect of changes in lymphocyte subsets at diagnosis in acute myeloid leukemia on prognosis: association with complete remission rates and relapse free survivals.
Park SH; Bae MH; Park CJ; Cho YU; Jang S; Lee JH; Lee KH
J Hematop; 2023 Jun; 16(2):73-84. PubMed ID: 38175440
[TBL] [Abstract][Full Text] [Related]
3. Uncovering the cellular and omics characteristics of natural killer cells in the bone marrow microenvironment of patients with acute myeloid leukemia.
Zhang L; Sun Y; Xue CE; Wang S; Xu X; Zheng C; Chen C; Kong D
Cancer Cell Int; 2024 Mar; 24(1):106. PubMed ID: 38481242
[TBL] [Abstract][Full Text] [Related]
4. Anti-Leukemic Properties of Histamine in Monocytic Leukemia: The Role of NOX2.
Kiffin R; Grauers Wiktorin H; Nilsson MS; Aurelius J; Aydin E; Lenox B; Nilsson JA; Ståhlberg A; Thorén FB; Hellstrand K; Martner A
Front Oncol; 2018; 8():218. PubMed ID: 29967760
[TBL] [Abstract][Full Text] [Related]
5. Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30.
Kellner C; Günther A; Humpe A; Repp R; Klausz K; Derer S; Valerius T; Ritgen M; Brüggemann M; van de Winkel JG; Parren PW; Kneba M; Gramatzki M; Peipp M
Oncoimmunology; 2016; 5(1):e1058459. PubMed ID: 26942070
[TBL] [Abstract][Full Text] [Related]
6. Human CD56bright NK Cells: An Update.
Michel T; Poli A; Cuapio A; Briquemont B; Iserentant G; Ollert M; Zimmer J
J Immunol; 2016 Apr; 196(7):2923-31. PubMed ID: 26994304
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitors enhance cytotoxicity of cytokine-induced killer cells against human myeloid leukaemic blasts.
Poh SL; Linn YC
Cancer Immunol Immunother; 2016 May; 65(5):525-36. PubMed ID: 26961084
[TBL] [Abstract][Full Text] [Related]
8. Natural killer cell immunotherapy to target stem-like tumor cells.
Grossenbacher SK; Canter RJ; Murphy WJ
J Immunother Cancer; 2016; 4():19. PubMed ID: 27096096
[TBL] [Abstract][Full Text] [Related]
9. Natural killer cells in acute myeloid leukemia patients: from phenotype to transcriptomic analysis.
Venton G; Labiad Y; Colle J; Fino A; Afridi S; Torres M; Monteuil S; Loriod B; Fernandez-Nunez N; Farnault L; Suchon P; Mattei JC; Rihet P; Bergon A; Nguyen C; Baier C; Costello R
Immunol Res; 2016 Dec; 64(5-6):1225-1236. PubMed ID: 27481509
[TBL] [Abstract][Full Text] [Related]
10. The antileukemic potential of natural killer cells.
Torelli GF; Peragine N; Mariglia P; Foà R
Immunotherapy; 2016; 8(4):425-34. PubMed ID: 26973124
[TBL] [Abstract][Full Text] [Related]
11. Relapse Prevention in Acute Myeloid Leukemia: The Role of Immunotherapy with Histamine Dihydrochloride and Low-Dose Interleukin-2.
Montesinos P; Buccisano F; Cluzeau T; Vennström L; Heuser M
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791903
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-2 is required for NKp30-dependent NK cell cytotoxicity by preferentially regulating NKp30 expression.
Kim N; Yi E; Lee E; Park HJ; Kim HS
Front Immunol; 2024; 15():1388018. PubMed ID: 38698855
[TBL] [Abstract][Full Text] [Related]
13. NKG2A gene variant predicts outcome of immunotherapy in AML and modulates the repertoire and function of NK cells.
Hussein BA; Kristenson L; Pesce S; Wöhr A; Tian Y; Hallner A; Brune M; Hellstrand K; Tang KW; Bernson E; Thorén FB
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37648262
[TBL] [Abstract][Full Text] [Related]
14. HLA-B*44 and the Bw4-80T motif are associated with poor outcome of relapse-preventive immunotherapy in acute myeloid leukemia.
Komic H; Hallner A; Hussein BA; Badami C; Wöhr A; Hellstrand K; Bernson E; Thorén FB
Cancer Immunol Immunother; 2023 Nov; 72(11):3559-3566. PubMed ID: 37597015
[TBL] [Abstract][Full Text] [Related]
15. Combined flow cytometry natural killer immunophenotyping and KIR/HLA-C genotyping reveal remarkable differences in acute myeloid leukemia patients, but suggest an overall impairment of the natural killer response.
Cianga VA; Rusu C; Pavel-Tanasa M; Dascalescu A; Danaila C; Harnau S; Aanei CM; Cianga P
Front Med (Lausanne); 2023; 10():1148748. PubMed ID: 36960339
[TBL] [Abstract][Full Text] [Related]
16. Impact of NK Cell Activating Receptor Gene Variants on Receptor Expression and Outcome of Immunotherapy in Acute Myeloid Leukemia.
Hussein BA; Hallner A; Wennström L; Brune M; Martner A; Hellstrand K; Bernson E; Thorén FB
Front Immunol; 2021; 12():796072. PubMed ID: 34956230
[TBL] [Abstract][Full Text] [Related]
17. Histamine in cancer immunology and immunotherapy. Current status and new perspectives.
Sarasola MP; Táquez Delgado MA; Nicoud MB; Medina VA
Pharmacol Res Perspect; 2021 Oct; 9(5):e00778. PubMed ID: 34609067
[TBL] [Abstract][Full Text] [Related]
18. Impact of IL-1β and the IL-1R antagonist on relapse risk and survival in AML patients undergoing immunotherapy for remission maintenance.
Grauers Wiktorin H; Aydin E; Christenson K; Issdisai N; Thorén FB; Hellstrand K; Martner A
Oncoimmunology; 2021; 10(1):1944538. PubMed ID: 34367728
[TBL] [Abstract][Full Text] [Related]
19. Natural Killer Cell Subpopulations and Inhibitory Receptor Dynamics in Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Cianga VA; Campos Catafal L; Cianga P; Pavel Tanasa M; Cherry M; Collet P; Tavernier E; Guyotat D; Rusu C; Aanei CM
Front Immunol; 2021; 12():665541. PubMed ID: 33986753
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
